AB084. Docetaxel therapy for hormone-sensitive prostate cancer—single center result

Background: Androgen-deprivation therapy (ADT) has been the treatment for metastatic prostate cancer for more 75 years. We assessed whether concomitant treatment with ADT added to docetaxel would result in patients newly-diagnosed metastatic hormone-sensitive prostate cancer for longer overall survival.

Methods and Materials: Since August 2014, 14 patients with metastatic, hormone-sensitive prostate cancer received ADT plus docetaxel (at a dose of 75 mg per square meter of body-surface area every 3 weeks for six cycles). The primary objective was to test the hypothesis that the median overall survival would be more longer among patients receiving docetaxel added to ADT early during therapy.

Results: After six cycles of docetaxel added to ADT therapy, four patients PSA level reduced less than 0.2 ng/mL and observe the withdrawal; one patient PSA rise to 4 ng/mL received ADT treatment again; one patient had grade 3 blood toxicity. None grade 4 blood toxicity occurred.

Conclusions: Patients with hormone-sensitive metastatic prostate cancer overall survival prolonged significantly after ADT + D therapy; 6-cycle chemotherapy were recommended; the benefit for docetaxel therapy was found to be more apparent in the high-volume metastatic group.

Keywords: Hormone-sensitive prostate cancer; docetaxel; androgen-deprivation therapy (ADT)